1 |
Candidate Treponema pallidum biomarkers uncovered in urine from individuals with syphilis using mass spectrometryOsbak, K.K., Van Raemdonck, G.A., Dom, M., Cameron, C.E., Meehan, Conor J., Deforce, D., Van Ostade, X., Kenyon, C.R., Dhaenens, M. 05 November 2019 (has links)
No / Aim: A diagnostic test that could detect Treponema pallidum antigens in urine would facilitate the prompt diagnosis of syphilis. Materials & methods: Urine from 54 individuals with various clinical stages of syphilis and 6 controls were pooled according to disease stage and interrogated with complementary mass spectrometry techniques to uncover potential syphilis biomarkers. Results & conclusion: In total, 26 unique peptides were uncovered corresponding to four unique T. pallidum proteins that have low genetic sequence similarity to other prokaryotes and human proteins. This is the first account of direct T. pallidum protein detection in human clinical samples using mass spectrometry. The implications of these findings for future diagnostic test development is discussed. Data are available via ProteomeXchange with identifier PXD009707.
|
2 |
The Relationship between Perceived Personal Risk of getting Prostate cancer and Prostate-Specific Antigen (PSA) ScreeningMcIntosh, Yeatoe G. 01 August 2008 (has links)
Abstract Title: The Relationship between Perceived Personal Risk of getting Prostate cancer and Prostate-Specific Antigen (PSA) Screening Yeatoe G. McIntosh, MPH Candidate Advisor: Emmanuel Anum, MBChB, MPH, PHD Preceptor: Emmanuel Anum, MBChB, MPH, PHD Background: Prostate cancer is one of the most common cancer diagnoses in the United States. The American Cancer Society estimates that in 2008 28,660 deaths would be attributed to prostate cancer, projecting it to be the leading cause of cancer deaths in U.S. men. Despite the potential threat this cancer presents to men and the potential for improved disease outcomes from early detection, guidelines for screening for prostate cancer are varied, and disparities in screening prevalence exist. In addition, disparities in knowledge about prostate cancer screening and misconceptions about the disease seem widespread. The main purpose of this study was to determine the relationship between perceived personal risk of getting prostate cancer and prostate cancer screening with the Prostate-specific antigen (PSA) test. Methods: Data were collected from the 2003 Health Information National Trends Survey (HINTS). Overall, 1,815 men ages 35 and above were included in the sample after exclusion of men ages 18-34. Logistic regression analyses were conducted to assess the association between perceived personal risk and prostate cancer screening with PSA test, while testing for interaction and further adjusting for possible confounders. A reduced model, in which variables with non-significant Wald chi-squared statistic had been excluded, was compared to the full model to access the change in parameter estimates. Using the model-based approach, we compared models with interaction terms to the one without interaction terms using the likelihood ratio test. Parameter estimates from the best fitting model were reported using the design-based method. SAS version 9.1 statistical software was used for analyses. Results: Among men ages 35-49, those who perceived their risk as high, were significantly less likely to screen than those who perceived their risk as low (OR: 0.20 95% CI: 0.05-0.78). Within ages 50-64 and 65 and above, there were no significant differences between perceived risk levels and PSA testing. Men, who did receive healthcare provider recommendation for screening, were more likely to obtain prostate cancer (PSA) screening than men who did not receive such recommendation (OR: 92.56 95% CI 36.56, 234.36). Conclusions: The relationship between perceived personal risk of getting prostate cancer and PSA screening is modified by age. As men aged, their odds of screening increased. The most significant predictor of PSA screening was health provider recommendation. PSA screening showed no association with either race or household income.
|
3 |
Prostate Cancer and PSA Testing: Implications of Provider-Patient Communication and Shared- Decision Making on National Screening RecommendationsReece, Michelle C 01 August 2014 (has links)
The national recommendations for use of the prostate specific antigen (PSA) test for prostate cancer screening have been modified over the years as scientific evidence emerged. Current screening recommendations discourage widespread PSA screening for men at low to average risk, but provide specific guidelines for shared-decision making between men and their health providers about the benefits and risks of PSA testing. This study was an examination of relationships between men’s assessment of the quality of their care and communication with their health providers, the extent to which providers engage men in recommended discussions about PSA testing, and factors associated with shared-decision making and PSA testing. Secondary data from the U.S. Health Information National Trends Survey 4, Cycle 2 that included men with no history of prostate cancer and in the recommended age ranges for prostate cancer screening were analyzed (N=777). Non-Hispanic white men rated their quality of care higher than men of other races (c2 (49, n=635) = 7.23, p = 0.0098), whereas Hispanic men gave the lowest ratings compared to other men (c2 (49, n=635) = 5.42, p = 0.024). Previous PSA testing was reported by 64% of the men, 56% of whom stated that they discussed screening with their provider and 80% reported that they were asked if they wanted to have the test done. However, only 21% - 39% reported having ever discussed the pros and cons of PSA testing. Discussing PSA testing with a provider was the strongest predictor of obtaining the test (OR=69.5, CI = 23.6 – 204.6) but the effect was significantly modified when providers and patients engaged in the shared-decision making process (OR = 47.42, CI = 14.91 – 150.74). Age, education level and perceived quality of care were consistent, positive predictors of PSA testing. These results indicate there is a gap in provider-patient discussions about PSA screening and suggest that health providers may not be following the recommended guidelines for the content of the discussions needed to facilitate shared-decision making. Effective provider-based interventions to increase shared-decision-making about PSA testing are needed if the national objectives for prostate cancer screening are to be met.
|
4 |
Utvärdering av icke-invasiva metoder för diagnostik av Helicobacter pylori-infektion : En systematisk litteraturstudieGonzalez Elfwing, Olivia, Nilsson, Elin January 2020 (has links)
Helicobacter pylori-infektion är en av de ledande orsakerna till utvecklingen av maligniteter i ventrikeln. Tillämpning av pålitliga analytiska metoder är därför väsentlig för en korrekt diagnostik och behandling av infektionen. Syftet med studien var att ge en översikt av icke-invasiva metoder som tillämpas för påvisning av H. pylori och utvärdera vilken metod som är bäst lämpad, med avseende på metodens prestandaegenskaper och det kliniska tillståndet hos patienten. En systematisk litteraturöversikt utfördes, genom sökning efter vetenskapliga artiklar med inklusions- och exklusionskriterier i databaserna PubMed och CINAHL. Utvalda artiklar kvalitetsgranskades och 20 studier inkluderades i resultatet. Sammanställt hade fecesantigentester en sensitivitet och specificitet på 92,64% respektive 91,47%, antikroppstester hade 97,20% respektive 81,59%, urea utandningstester hade 91,40% respektive 91,70% och polymeraskedjereaktionen hade 75,45% respektive 98,30%. Därutöver hade kliniska tillstånd såsom atrofisk gastrit, intestinal metaplasi och gastrointestinal blödning en negativ påverkan på metodernas diagnostiska tillförlitlighet. Studien konstaterade att beträffande metodens prestanda är fecesantigentester mest lämpliga för påvisning av H. pylori- infektion. Vid allvarligare kliniska åkommor bör minst två icke-invasiva diagnostiska metoder tillämpas för att säkerställa pålitliga resultat. / Helicobacter pylori infection is one of the leading causes of ventricular pathologies. Reliable analytic methods are therefore crucial for the correct diagnosis and treatment of the infection. The aim of this study was to provide an overview of non-invasive diagnostic methods used for the detection of H. pylori and to evaluate which method is most suitable, considering its performance and the clinical condition of the patient. A systematic literature review was conducted, searching peer-reviewed research articles with inclusion and exclusion criteria on the databases PubMed and CINAHL. An assessment of the selected articles quality resulted in the inclusion of 20 articles. Overall, stool antigen tests had a sensitivity and specificity of 92,64% and 91,47% respectively, antibody tests 97,20% and 81,59% respectively, urea breath tests 91,40% and 91,70% respectively, and the polymerase chain reaction 75,45% and 98,30% respectively. Furthermore, conditions such as atrophic gastritis, intestinal metaplasia and gastrointestinal bleeding had a negative impact on the diagnostic accuracy of the methods. This study concluded that, regarding the methods performance, stool antigen tests are more suitable for detecting a H. pylori infection. With the mentioned clinical conditions, at least two non- invasive diagnostic methods should be used to ensure reliable results.
|
Page generated in 0.0702 seconds